Literature DB >> 28103602

Intraocular Cytokines and Their Correlations with Clinical Parameters in Patients with Myopic Choroidal Neovascularization.

Andrey G Shchuko1, Natalia V Zaitseva, Tatyana N Yurieva, Elena R Chernykh, Isay M Mikhalevich, Ekaterina Y Shevela, Alina V Grigorieva.   

Abstract

PURPOSE: To study cytokine levels in aqueous humor of patients with myopic choroidal neovascularization (mCNV), their correlations with each other and ocular parameters.
METHODS: Ophthalmological examination and immunological study of aqueous humor with cytokine levels measurement (Bio-Plex™ Human Cytokine 27-Plex panel; Bio-Rad Laboratories, USA) were performed in 19 patients (19 eyes) with ranibizumab-treated mCNV and compared to 15 patients (15 eyes) with myopia without CNV.
RESULTS: The levels of 10 cytokines were significantly different in patients with mCNV compared to the controls: the vascular endothelial growth factor (VEGF) level was 2 times lower (191.15 ± 142.30 and 320.06 ± 170.05 pg/mL, respectively), and the levels of PDGF, IL-2, IL-5, IL-13, IL-15, IL-17А, TNF-α, IL-8, and RANTES were elevated. Strong correlations between morphological and functional parameters and cytokines, including VEGF, were found. The VEGF level inversely correlated with the myopia degree and the cytokines IL-13, INF-γ, and RANTES.
CONCLUSION: The decrease in VEGF levels accompanied by imbalance of other cytokines may suggest additional mCNV development pathways.
© 2017 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28103602     DOI: 10.1159/000455271

Source DB:  PubMed          Journal:  Ophthalmologica        ISSN: 0030-3755            Impact factor:   3.250


  1 in total

1.  Specific ablation of PDGFRβ-overexpressing pericytes with antibody-drug conjugate potently inhibits pathologic ocular neovascularization in mouse models.

Authors:  Seok Jae Lee; Soohyun Kim; Dong Hyun Jo; Chang Sik Cho; Su Ree Kim; Dongmin Kang; Jisu Chae; Duck Kyun Yoo; Suji Ha; Junho Chung; Jeong Hun Kim
Journal:  Commun Med (Lond)       Date:  2021-12-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.